Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review.

Background: Prostate cancer (PC) is one of the most common cancers in men. Although the overall prognosis is favorable, the management of metastatic castration-resistant prostate cancer (mCRPC) patients is challenging. Usually, mCRPC patients with progressive disease are considered for radioligand therapy (RLT) after exhaustion of other standard treatments.